14 recruiting, 13 completed, 10 active not recruiting, 9 terminated. 32 Phase 1, 29 Phase 2, 2 Not applicable, 1 Early Phase 1, 1 Phase 3.
Follow Refractory Acute Lymphoblastic Leukemia: new trials by email Literature Review of Refractory Acute Lymphoblastic Leukemia trials Research Report on Refractory Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia Autologous Anti-CD19/CD20/CD22 CAR T-cells, Biospecimen Collection, Bone Marrow Aspiration - Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive, Recurrent Acute Lymphoblastic Leukemia | Phase 1 | Active not recruiting | Ohio State University Comprehensive Cancer Center | 24 | 2026-01-14 | 2026-08-26 |
| A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies Autologous CD5 CAR T-cells, Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells, Newly matched donor-derived CD5 CAR T-cells - T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 54 | 2025-07-09 | 2025-11-26 |
| CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia Fludarabine, Cyclophosphamide, Mesna - Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 25 | 2025-05-21 | 2026-03-25 |
| Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia | Phase 1 | Suspended | City of Hope Medical Center | 24 | 2024-11-06 | 2026-06-05 |
| Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL MC-1-50 - Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | Phase 1 | Not yet recruiting | Chongqing Precision Biotech Co., Ltd | 24 | 2024-11-01 | 2024-10-15 |
| Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia Senl_B19 autologous CAR-T (S1904) treatment - Relapsed Adult ALL, B-cell Acute Lymphoblastic Leukemia | Not applicable | Recruiting | Peking University People's Hospital | 130 | 2024-10-01 | 2025-03-12 |
| CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies Autologous CD5 CAR T-cells, Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells, Newly matched donor-derived CD5 CAR T-cells - T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 54 | 2024-06-18 | 2026-03-10 |
| Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies Autologous CD7 CAR T-cell, Prior-HSCT donor-derived CD7 CAR T-cell, New donor-derived CD7 CAR T-cell - T-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 80 | 2024-03-22 | 2025-11-26 |
| A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL) 19-28z/IL-18 CAR T cells - Philadelphia-Negative ALL, Philadelphia-Positive ALL | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 18 | 2024-02-23 | 2026-02-10 |
| A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol - Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Children's Oncology Group | 78 | 2024-01-08 | 2026-08-25 |
| ThisCART19A Bridging to alloHSCT for R/R B-ALL Treatment - CAR, Refractory Acute Lymphoblastic Leukemia | Phase 1 | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2022-12-01 | 2023-01-11 |
| Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax Venetoclax, Navitoclax, Dexamethasone - Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 35 | 2022-08-25 | 2026-10-15 |
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate - Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Sumithira Vasu | 54 | 2022-06-30 | 2026-05-29 |
| Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children Murine autologous anti-CD19 chimeric antigen receptor T cells - Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia, in Relapse | Phase 2 | Completed | Beijing Boren Hospital | 2 | 2022-03-24 | 2025-05-18 |
| A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents pCAR-19B cells - Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL | Phase 2 | Recruiting | Chongqing Precision Biotech Co., Ltd | 100 | 2022-01-26 | 2026-09-15 |
| Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia Palbociclib, Dexamethasone, Bortezomib - Acute Lymphoblastic Leukemia, Pediatric, Relapsed Acute Lymphoblastic Leukemia | Phase 1 | Completed | Tanja Andrea Gruber | 2 | 2021-07-09 | 2026-04-17 |
| Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia Cytarabine, Fludarabine, Pegcrisantaspase - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-09 | 2024-12-12 |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 17 | 2021-03-25 | 2025-05-23 |
| Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL pCAR-19B cells - Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | Phase 1 | Unknown | Chongqing Precision Biotech Co., Ltd | 18 | 2020-10-26 | 2021-05-17 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Withdrawn | City of Hope Medical Center | 2020-10-20 | 2020-12-17 |
Showing 20 of 54. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (54) · Leukemia, Myeloid, Acute (18) · Leukemia, Biphenotypic, Acute (11) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (9) · Blast Crisis (8) · Burkitt Lymphoma (8) · Leukemia, Myelomonocytic, Chronic (8) · Leukemia, Myeloid, Accelerated Phase (7) · Lymphoma, Non-Hodgkin (7) · Myelodysplastic Syndromes (7) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Anemia, Refractory, with Excess of Blasts (5) · Hodgkin Disease (5) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (5) · Hematologic Neoplasms (4)
Hematologic Diseases (54) · Hemic and Lymphatic Diseases (54) · Immune System Diseases (54) · Immunoproliferative Disorders (54) · Lymphatic Diseases (54) · Lymphoproliferative Disorders (54) · Neoplasms (54) · Neoplasms by Histologic Type (54) · Leukemia (53) · Leukemia, Lymphoid (52) · Leukemia, Myeloid (23) · Pathologic Processes (21) · Pathological Conditions, Signs and Symptoms (21) · Disease Attributes (20) · Chronic Disease (19)
Cyclophosphamide (15) · Vincristine (9) · CT-P10 (8) · Cytarabine (8) · Methotrexate (8) · Rituximab (8) · fludarabine phosphate (8) · Calcium Dobesilate (7) · Dexamethasone (7) · Specimen Handling (6) · Whole-Body Irradiation (6) · merphos (6) · Biopsy (5) · Mycophenolic Acid (5) · blinatumomab (5)
M.D. Anderson Cancer Center (13) · Fred Hutchinson Cancer Center (5) · Chongqing Precision Biotech Co., Ltd (4) · City of Hope Medical Center (4) · Beijing GoBroad Hospital (3) · Beijing Boren Hospital (2) · OHSU Knight Cancer Institute (2) · St. Jude Children's Research Hospital (2) · Children's Hospital Medical Center, Cincinnati (1) · Children's Mercy Hospital Kansas City (1) · Children's Oncology Group (1) · Chinese PLA General Hospital (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Julio Barredo, MD (1)
United States (40) · China (12) · Canada (1) · Russia (1) · Spain (1)
Elias Jabbour (3) · Ibrahim Aldoss (2) · Jianfeng Zhou, M.D. Ph.D (2) · Sumithira Vasu, MD (2) · Tapan M Kadia (2) · Aimee Talleur, MD (1) · Akil Merchant, MD (1) · Amanda Olson (1) · Anjali S Advani (1) · Bijal Shah, M.D. (1) · Brenda M. Sandmaier (1) · Chandni Dargan, MD (1) · Chitra Hosing (1) · Crystal Mackall (1) · Elias Jabbour, MD (1)
PMID 27111235, PMID 29038338, PMID 30335787, PMID 30728140, PMID 30729531, PMID 30782611, PMID 31648294, PMID 32929049, PMID 32967009, PMID 34515338, PMID 34666344, PMID 34889384, PMID 35007144, PMID 35622074, PMID 36322825, PMID 36402146, PMID 36775248, PMID 36841758, PMID 37774014, PMID 38683966, PMID 39028925, PMID 39333103, PMID 39863139, PMID 40246579, PMID 40369607, PMID 41039358, PMID 41671463, PMID 42341322, PMID 42389828
P01CA078902 (2), P30CA015704 (2), P30CA016672 (2), P01CA018029 (1), P30CA014089 (1), P30CA033572 (1), P50CA107399 (1), R01CA136551 (1), R01CA211044 (1), R01CA276374 (1), R01HL121568 (1), R21CA159265 (1), U10CA180886 (1), U10CA180888 (1)